Ali v. Carnegie Institution of Washington

306 F.R.D. 20, 89 Fed. R. Serv. 3d 537, 2014 U.S. Dist. LEXIS 120762, 2014 WL 4260995
CourtDistrict Court, District of Columbia
DecidedAugust 29, 2014
DocketCivil Action No. 2013-2030
StatusPublished
Cited by8 cases

This text of 306 F.R.D. 20 (Ali v. Carnegie Institution of Washington) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ali v. Carnegie Institution of Washington, 306 F.R.D. 20, 89 Fed. R. Serv. 3d 537, 2014 U.S. Dist. LEXIS 120762, 2014 WL 4260995 (D.D.C. 2014).

Opinion

Re Document No.: 73

MEMORANDUM OPINION

Granting Carnegie’s Motion to Dismiss

RUDOLPH CONTRERAS, United States District Judge

I. INTRODUCTION

The present action arises out of the Plaintiffs claim that he was erroneously omitted as an inventor on five U.S. patents co-owned by the Defendant, the Carnegie Institution of Washington (“Carnegie”) and the University of Massachusetts (“UMass”), originally brought in the U.S. District Court for the District of Oregon. The Oregon court transferred the action to this Court pursuant to 28 U.S.C. § 1406(a). Carnegie now moves to dismiss the Plaintiffs Amended Complaint under Federal Rule of Civil Procedure 12(b)(7), for failure to join a necessary party, or in the alternative, under Federal Rule of Civil Procedure 12(b)(6) for failure to state a claim. For the following reasons, the Court grants Carnegie’s motion to dismiss under Rule 12(b)(7).

II. FACTUAL BACKGROUND

Plaintiff Mussa Ali seeks, pursuant to 35 U.S.C. § 256 (“§ 256”), to correct the inven-torship on five U.S. patents. 1 Am. Compl. ¶ 1, ECF No. 4. Carnegie and UMass are co-owners, by assignment, of the patents at issue. Id. ¶¶ 3-4. The patents were allegedly issued as a result of the collaboration between Dr. Andrew Fire and Dr. Craig C. Mello, the two lead inventors of the laboratories of Carnegie and UMass, respectively. *24 See Def.’s Mot. Dismiss 4, ECF No. 73-1. The patents claim methods of inhibiting the expression of a particular gene in a cell through the introduction of a double stranded ribonucleic acid (“RNA”) molecule. Am. Compl. ¶ 19. As a result of the discovery of this process, called RNA interference (“RNAi”), the two lead inventors were awarded the Nobel Prize in Medicine in 2006. See Def.’s Mot. Dismiss 1.

The Plaintiff alleges that he made a critical contribution to the discovery of RNAi, which is central to the claims in each of the patents, while working at UMass in Dr. Mello’s laboratory, and that Dr. Mello then shared his discovery with Dr. Fire. See Am. Compl. ¶¶ 8-20; see also Pl.’s Opp’n Mot. 3, ECF No. 75. The Plaintiff subsequently approached Carnegie and UMass on numerous occasions seeking to be named a co-inventor. Id. When those attempts failed, the Plaintiff filed his original complaint and his Amended Complaint against Carnegie and UMass in the U.S. District Court for the District of Oregon in September and December 2012, respectively. See generally Compl, ECF No. 1; Am. Compl, ECF No. 4.

In his Amended Complaint, the Plaintiff asserted a claim to be named a co-inventor of the patents at issue under § 256 and two alternative claims for damages for the revenue derived from the patents, proceeds he alleges he is owed as a result of his role in the discovery of RNAi. See Am. Compl. Counts 1, 2, and Alternative Count 2. Ali’s alternative counts are titled “Legal Damages.” In Count 2 for Legal Damages, Ali alleges that “[o]n information and belief, during the time of Ali’s work at [UJMass, [UJMass had a policy that all [UJMass employees making inventions assigned, or had an obligation to assign, those inventions and all rights thereto, to [UJMass. In consideration of that assignment, [UJMass would pay the co-inventors a percentage of all revenue realized by [UJMass through exploitation of that invention, including licensing, to be shared equally between investors.” Am. Compl. ¶ 30. Ali further alleges that he “is entitled to a portion of all proceeds realized by [UJMass as a consequence of any sale, licensing, enforcement or threatened enforcement of any and all of the Patents____” Id. ¶ 31. In Alternative Count 2, Ali alleges that “[ojn information and belief, [UJMass and Carnegie have secured substantial fees by reason of selling, licensing, or otherwise transferring their rights in and to the Patents to third parties,” and that as such, “Ali is entitled to recover from [UJMass and Carnegie a portion of moneys they have secured by reason of selling, licensing, or otherwise transferring their rights in and to the Patents to third parties, as a reasonable measure of the moneys Ali would have been entitled to recover if properly named as a co-inventor from the filing date.” See Am. Compl. ¶¶ 35-36.

In two separate sets of opinions and orders, the District Court of Oregon first dismissed UMass from the ease on the basis of sovereign immunity and then ruled that the court lacked personal jurisdiction over Carnegie. See Op. & Order, ECF No. 41; Op. & Order, ECF No. 66. After the Oregon court transferred the case sua sponte to this Court pursuant to 28 U.S.C. § 1406(a), the Defendant moved to dismiss the case for failure to join a necessary party—UMass—or, in the alternative to dismiss or strike the Plaintiffs two alternative claims for damages. See Def.’s Mot. Dismiss 1-3. 2 Because the Court finds that UMass is a necessary party that must, but cannot be joined, and that the action cannot “in equity and good conscience” continue absent UMass, the Court will grant Carnegie’s motion to dismiss under Federal Rule of Civil Procedure 12(b)(7).

III. ANALYSIS

Carnegie first argues that the case should be dismissed in its entirety under Federal Rule of Civil Procedure 12(b)(7) because UMass must, but cannot, be joined. Specifically, Carnegie contends that UMass is a required party under Rule 19(a), but that UMass’s sovereign immunity precludes its joinder, effectively barring the Plaintiffs *25 claims. Thus, according to the Defendant, the complaint must be dismissed under Rule 19(b) because the case cannot proceed “in equity and good conscience” in UMass’s absence. Plaintiff meanwhile argues that UMass is not a necessary party under Rule 19(a), but that even if it were, it is not required to be joined under Rule 19(b). 3 The Court finds that UMass is a necessary party under Rule 19(a) and required to be joined under Rule 19(b), and as such, the case must be dismissed for failure to join UMass.

A. Legal Standard

Federal Rule of Civil Procedure 12(b)(7) provides for the dismissal of a complaint for “failure to join a party under Rule 19.” Fed. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bluestar Genomics v. Song
N.D. California, 2023
Yueh-Lan Wang Ex Rel. Wen-Young Wong v. New Mighty U.S. Trust
322 F.R.D. 11 (District of Columbia, 2017)
Statoil Oil & Gas, LP v. Abaco Energy, LLC
2017 ND 148 (North Dakota Supreme Court, 2017)
United States v. University of Massachusetts
167 F. Supp. 3d 221 (D. Massachusetts, 2016)
Ali v. Carnegie Institution of Washington
309 F.R.D. 77 (District of Columbia, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
306 F.R.D. 20, 89 Fed. R. Serv. 3d 537, 2014 U.S. Dist. LEXIS 120762, 2014 WL 4260995, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ali-v-carnegie-institution-of-washington-dcd-2014.